| Identification | Back Directory | [Name]
(8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate | [CAS]
1373431-65-2 | [Synonyms]
CS-2862
BMN-673 ts
TALAZOPARIB TOSYLATE
BMN-673;BMN673;BMN 673
BMN673; BMN673; BMN-673; L
Talazoparib tosylate (BMN 673ts)
(8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate
(8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido(4,3,2-de)phthalazin-3-one MONO(4-methylbenzenesulfonate) | [Molecular Formula]
C26H22F2N6O4S | [MDL Number]
MFCD31657366 | [MOL File]
1373431-65-2.mol | [Molecular Weight]
552.552 |
| Chemical Properties | Back Directory | [Melting point ]
>281°C (dec.) | [storage temp. ]
Hygroscopic, -20°C Freezer, Under inert atmosphere | [solubility ]
Acetone (Slightly, Heated, Sonicated), DMSO (Slightly), Methanol (Slightly) | [form ]
Solid | [color ]
Off-White to Pale Yellow | [Stability:]
Hygroscopic |
| Hazard Information | Back Directory | [Uses]
Talazoparib Tosylate is Quinoline derivative used for treating non-small cell lung cancer. | [in vivo]
Talazoparib is readily orally bioavailable, with more than 40% absolute oral bioavailability in rats when dosed in carboxylmethyl cellulose. Oral administration of Talazoparib elicits remarkable antitumor activity; xenografted tumors that carry defects in DNA repair due to BRCA mutations or PTEN deficiency are profoundly sensitive to oral Talazoparib treatment at well-tolerated doses in mice. Synergistic or additive antitumor effects are also found when Talazoparib is combined with temozolomide, SN38, or platinum drugs[1]. |
|
|